Reuters logo
BRIEF-Kindred Biosciences submits final major NADA technical section for Safety for Mirataz to FDA
September 30, 2016 / 1:36 PM / a year ago

BRIEF-Kindred Biosciences submits final major NADA technical section for Safety for Mirataz to FDA

Sept 30 (Reuters) - Kindred Biosciences Inc :

* Kindred Biosciences submits final major New Animal Drug Application technical section for Safety for Mirataz to FDA and launches KindredBio Equine website

* In target animal safety study, Mirataz was generally well-tolerated and no significant safety concerns were identified Source text for Eikon: Further company coverage: ;))

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below